Ibuprofen/paracetamol - Wellesley Pharmaceuticals

Drug Profile

Ibuprofen/paracetamol - Wellesley Pharmaceuticals

Alternative Names: Paxerol

Latest Information Update: 18 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wellesley Pharmaceuticals
  • Class Anti-inflammatories; Non-opioid analgesics; Phenylpropionates
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Nocturia

Most Recent Events

  • 01 Jan 2016 Phase-II clinical trials in Nocturia in USA (PO) (NCT02646826)
  • 30 Dec 2015 Preclinical trials in Nocturia in USA (PO)
  • 30 Dec 2015 Wellesley Pharmaceuticals plans a phase II trial for Nocturia in USA (NCT02646826)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top